Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis”

102 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 102 results

Post-approval studies (Phase 4)Study completedNCT02410278
What this trial is testing

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

Who this might be right for
Multiple Sclerosis
Biogen 102
Large-scale testing (Phase 3)Study completedNCT02980042
What this trial is testing

Safety of Switching From Rituximab to Ocrelizumab in MS Patients

Who this might be right for
Multiple Sclerosis
University of Colorado, Denver 200
Not applicableEnded earlyNCT04746976
What this trial is testing

Study of Diroximel Fumarate in the Real-World Setting

Who this might be right for
Relapsing Forms of MS
Biogen 75
Testing effectiveness (Phase 2)Study completedNCT00726648
What this trial is testing

CDP323 Biomarker Study

Who this might be right for
Relapsing Multiple Sclerosis
UCB Pharma 71
Large-scale testing (Phase 3)Study completedNCT04121221
What this trial is testing

Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Mapi Pharma Ltd. 1,016
Large-scale testing (Phase 3)Study completedNCT03277248
What this trial is testing

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Who this might be right for
Relapsing Multiple Sclerosis (RMS)
TG Therapeutics, Inc. 545
Large-scale testing (Phase 3)Study completedNCT04410991
What this trial is testing

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

Who this might be right for
Relapsing Multiple Sclerosis
Sanofi 899
Post-approval studies (Phase 4)Study completedNCT00536120
What this trial is testing

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Biogen 60
Testing effectiveness (Phase 2)Study completedNCT00640328
What this trial is testing

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

Who this might be right for
Multiple Sclerosis
GlaxoSmithKline 38
Large-scale testing (Phase 3)Study completedNCT00472797
What this trial is testing

Rebif New Formulation (RNF) Quality of Life (QOL) Study

Who this might be right for
Relapsing Multiple Sclerosis
EMD Serono 232
Large-scale testing (Phase 3)Study completedNCT04510220
What this trial is testing

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Relapsing Multiple Sclerosis
Brigham and Women's Hospital 10
Early research (Phase 1)Ended earlyNCT01318421
What this trial is testing

ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Elan Pharmaceuticals 12
Post-approval studies (Phase 4)Active Not RecruitingNCT06444113
What this trial is testing

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 24
Large-scale testing (Phase 3)Study completedNCT02545868
What this trial is testing

Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Hoffmann-La Roche 102
Not applicableStudy completedNCT01592097
What this trial is testing

Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS

Who this might be right for
Multiple Sclerosis
University of Southern California 51
Early research (Phase 1)Study completedNCT01585766
What this trial is testing

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing Forms
MedImmune LLC 56
Not applicableLooking for participantsNCT06681623
What this trial is testing

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

Who this might be right for
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Neurology Center of New England P.C. 20
Early research (Phase 1)Looking for participantsNCT06138132
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary Progressive
Stanford University 12
Testing effectiveness (Phase 2)Ended earlyNCT01950234
What this trial is testing

ACTH in Progressive Forms of MS

Who this might be right for
Secondary Progressive Multiple SclerosisPrimary Progressive Multiple SclerosisProgressive Relapsing Multiple Sclerosis
University of Minnesota 59
Large-scale testing (Phase 3)Study completedNCT05028634
What this trial is testing

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Celgene 63
Next Page